Toxin-based targeted therapy for malignant brain tumors

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Chandramohan, Vidyalakshmi ^a   Sampson, John H ^a   Pastan, Ira ^b   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRM 107; CYTOTOXIN; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GLYCOPROTEIN; GLYCOPROTEIN NONMETASTATIC MELANOMA PROTEIN B; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN; IMMUNOTOXIN; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; MEMBRANE PROTEIN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RICIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; HYBRID PROTEIN; TUMOR ANTIGEN;

BRAIN CANCER; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; BRAIN TUMOR; CLINICAL TRIAL (TOPIC); GLIOMA; IMMUNOLOGY; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MORTALITY; PERSONALIZED MEDICINE; PROTEOMICS; SURVIVAL; TUMOR MICROENVIRONMENT;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; IMMUNOTOXINS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROTEOMICS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84858208091     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/480429     Document Type: Review

References (147)

1. Louis D. N., Gusella J. F., A tiger behind many doors: multiple genetic pathways to malignant glioma Trends in Genetics 1995 11 10 412 415
2. Keles G. E., Anderson B., Berger M. S., The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere Surgical Neurology 1999 52 4 371 379 (Pubitemid 29505267)
3. Leibel S. A., Scott C. B., Loeffler J. S., Contemporary approaches to the treatment of malignant gliomas with radiation therapy Seminars in Oncology 1994 21 2 198 219 (Pubitemid 24125959)
4. Lesser G. J., Grossman S., The chemotherapy of high-grade astrocytomas Seminars in Oncology 1994 21 2 220 235 (Pubitemid 24125960)
5. Stupp R., Hegi M. E., Mason W. P., van den Bent M. J., Taphoorn M. J., Janzer R. C., Ludwin S. K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A. A., Gijtenbeek J., Marosi C., Vecht C. J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J. G., Mirimanoff R. O., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial The Lancet Oncology 2009 10 5 459 466
6. Reardon D. A., Desjardins A., Peters K. B., Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy Cancer 2011 117 23 5351 5358
7. Constine L. S., Woolf P. D., Cann D., Mick G., McCormick K., Raubertas R. F., Rubin P., Hypothalamic-pituitary dysfunction after radiation for brain tumors The New England Journal of Medicine 1993 328 2 87 94
8. Imperato J. P., Paleologos N. A., Vick N. A., Effects of treatment on long-term survivors with malignant astrocytomas Annals of Neurology 1990 28 6 818 822
9. Furnari F. B., Fenton T., Bachoo R. M., Mukasa A., Stommel J. M., Stegh A., Hahn W. C., Ligon K. L., Louis D. N., Brennan C., Chin L., DePinho R. A., Cavenee W. K., Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes and Development 2007 21 21 2683 2710 (Pubitemid 350070717)
10. Sathornsumetee S., Reardon D. A., Desjardins A., Quinn J. A., Vredenburgh J. J., Rich J. N., Molecularly targeted therapy for malignant glioma Cancer 2007 110 1 12 24 (Pubitemid 46986413)
11. Herlyn M., Menrad A., Koprowski H., Structure, function, and clinical significance of human tumor antigens Journal of the National Cancer Institute 1990 82 24 1883 1889
12. Siegall C. B., Targeted toxins as anticancer agents Cancer 1994 74 3 1006 1012 (Pubitemid 24231995)
13. Moolten F. L., Cooperband S. R., Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells Science 1970 169 3940 68 70
14. Pastan I., Hassan R., FitzGerald D. J., Kreitman R. J., Immunotoxin treatment of cancer Annual Review of Medicine 2007 58 221 237 (Pubitemid 46706511)
15. Olsnes S., Refsnes K., Pihl A., Mechanism of action of the toxic lectins abrin and ricin Nature 1974 249 5468 627 631
16. Weldon J. E., Pastan I., A guide to taming a toxinrecombinant immunotoxins constructed from pseudomonas exotoxin a for the treatment of cancer FEBS Journal 2011 278 23 4683 4700
17. Carrasco L., Fernandez Puentes C., Vazquez D., Effects of ricin on the ribosomal sites involved in the interaction of the elongation factors European Journal of Biochemistry 1975 54 2 499 503
18. Yamaizumi M., Mekada E., Uchida T., Okada Y., One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell Cell 1978 15 1 245 250 (Pubitemid 9027527)
19. Eiklid K., Olsnes S., Pihl A., Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells Experimental Cell Research 1980 126 2 321 326 (Pubitemid 10041165)
20. Allured V. S., Collier R. J., Carroll S. F., McKay D. B., Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution Proceedings of the National Academy of Sciences of the United States of America 1986 83 5 1320 1324 (Pubitemid 16016120)
21. Hwang J., Fitzgerald D. J., Adhya S., Pastan I., Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli Cell 1987 48 1 129 136
22. Kounnas M. Z., Morris R. E., Thompson M. R., FitzGerald D. J., Strickland D. K., Saelinger C. B., The 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A Journal of Biological Chemistry 1992 267 18 12420 12423
23. Pastrana D. V., Hanson A. J., Knisely J., Bu G., FitzGerald D. J., LRP1B functions as a receptor for Pseudomonas exotoxin Biochimica et Biophysica Acta 2005 1741 3 234 239 (Pubitemid 41338668)
24. Siegall C. B., Chaudhary V. K., FitzGerald D. J., Pastan I., Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin Journal of Biological Chemistry 1989 264 24 14256 14261 (Pubitemid 19214253)
25. FitzGerald D. J. P., Trowbridge I. S., Pastan I., Willingham M. C., Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus Proceedings of the National Academy of Sciences of the United States of America 1983 80 13 I 4134 4138 (Pubitemid 13072782)
26. Greenfield L., Bjorn M. J., Horn G., Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage Proceedings of the National Academy of Sciences of the United States of America 1983 80 22 6853 6857 (Pubitemid 14243241)
27. Naglich J. G., Metherall J. E., Russell D. W., Eidels L., Expression cloning of a Diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor Cell 1992 69 6 1051 1061
28. Tsuneoka M., Nakayama K., Hatsuzawa K., Komada M., Kitamura N., Mekada E., Evidence for involvement of furin in cleavage and activation of diphtheria toxin Journal of Biological Chemistry 1993 268 35 26461 26465 (Pubitemid 23361724)
29. Sandvig K., Olsnes S., Diphtheria toxin entry into cells is facilitated by low pH Journal of Cell Biology 1980 87 3 828 832 (Pubitemid 11161814)
30. Collier R. J., Pappenheimer A. M. Jr., Studies on the mode of action of diphtheria toxin. II. Effect of toxin on amino acid incorporation in cell-free systems Journal of Experimental Medicine 1964 120 1019 1039
31. Honjo T., Nishizuka Y., Hayaishi O., Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis Journal of Biological Chemistry 1968 243 12 3553 3555
32. Van Ness B. G., Howard J. B., Bodley J. W., ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products Journal of Biological Chemistry 1980 255 22 10717 10720
33. Lamb F. I., Roberts L. M., Lord J. M., Nucleotide sequence of cloned cDNA coding for preproricin European Journal of Biochemistry 1985 148 2 265 270
34. Olsnes S., Pihl A., Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis Biochemistry 1973 12 16 3121 3126
35. Newton D. L., Wales R., Richardson P. T., Walbridge S., Saxena S. K., Ackerman E. J., Roberts L. M., Lord J. M., Youle R. J., Cell surface and intracellular functions for ricin galactose binding Journal of Biological Chemistry 1992 267 17 11917 11922
36. Sperti S., Montanaro L., Mattioli A., Stirpe F., Inhibition by ricin of protein synthesis in vitro: 60 S ribosomal subunit as the target of the toxin Biochemical Journal 1973 136 3 813 815
37. Endo Y., Mitsui K., Motizuki M., Tsurugi K., The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins Journal of Biological Chemistry 1987 262 12 5908 5912
38. Laske D. W., Youle R. J., Oldfield E. H., Tumor regression with regional distribution of the targeted toxin TF- CRM107 in patients with malignant brain tumors Nature Medicine 1997 3 12 1362 1368 (Pubitemid 28011036)
39. Weaver M., Laske D. W., Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) therapy of malignant gliomas Journal of Neuro-Oncology 2003 65 1 3 13 (Pubitemid 37441310)
40. Laske D. W., Muraszko K. M., Oldfield E. H., Devroom H. L., Sung C., Dedrick R. L., Simon T. R., Colandrea J., Copeland C., Katz D., Greenfield L., Groves E. S., Houston L. L., Youle R. J., Intraventricular immunotoxin therapy for leptomeningeal neoplasia Neurosurgery 1997 41 5 1039 1051 (Pubitemid 27475464)
41. Rand R. W., Kreitman R. J., Patronas N., Varricchio F., Pastan I., Puri R. K., Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma Clinical Cancer Research 2000 6 6 2157 2165 (Pubitemid 30399180)
42. Weber F., Asher A., Bucholz R., Berger M., Prados M., Chang S., Bruce J., Hall W., Rainov N. G., Westphal M., Warnick R. E., Rand R. W., Floeth F., Rommel F., Pan H., Hingorani V. N., Puri R. K., Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma Journal of Neuro-Oncology 2003 64 1-2 125 137 (Pubitemid 36992467)
43. Weber F. W., Floeth F., Asher A., Bucholz R., Berger M., Prados M., Chang S., Bruce J., Hall W., Rainov N. G., Westphal M., Warnick R. E., Rand R. W., Rommel F., Pan H., Hingorani V. N., Puri R. K., Local convection enhanced, delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma Acta Neurochirurgica, Supplementum 2003 88 93 103
44. Rainov N. G., Gorbatyuk K., Heidecke V., Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma Reviews on Recent Clinical Trials 2008 3 1 2 9 (Pubitemid 351267022)
45. Kunwar S., Prados M. D., Chang S. M., Berger M. S., Lang F. F., Piepmeier J. M., Sampson J. H., Ram Z., Gutin P. H., Gibbons R. D., Aldape K. D., Croteau D. J., Sherman J. W., Puri R. K., Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the cintredekin besudotox intraparenchymal study group Journal of Clinical Oncology 2007 25 7 837 844 (Pubitemid 350002884)
46. Kunwar S., Chang S., Westphal M., Vogelbaum M., Sampson J., Barnett G., Shaffrey M., Ram Z., Piepmeier J., Prados M., Croteau D., Pedain C., Leland P., Husain S. R., Joshi B. H., Puri R. K., Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma Neuro-Oncology 2010 12 8 871 881
47. Liu T. F., Hall P. D., Cohen K. A., Willingham M. C., Cai J., Thorburn A., Frankel A. E., Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice Clinical Cancer Research 2005 11 1 329 334 (Pubitemid 40075812)
48. Sampson J. H., Akabani G., Archer G. E., Bigner D. D., Berger M. S., Friedman A. H., Friedman H. S., Herndon J. E., Kunwar S., Marcus S., McLendon R. E., Paolino A., Penne K., Provenzale J., Quinn J., Reardon D. A., Rich J., Stenzel T., Tourt-Uhlig S., Wikstrand C., Wong T., Williams R., Yuan F., Zalutsky M. R., Pastan I., Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)- and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors Journal of Neuro-Oncology 2003 65 1 27 35 (Pubitemid 37441312)
49. Sampson J. H., Akabani G., Archer G. E., Berger M. S., Coleman R. E., Friedman A. H., Friedman H. S., Greer K., Herndon J. E. II, Kunwar S., McLendon R. E., Paolino A., Petry N. A., Provenzale J. M., Reardon D. A., Wong T. Z., Zalutsky M. R., Pastan I., Bigner D. D., Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors Neuro-Oncology 2008 10 3 320 329
50. Bullard D. E., Bigner D. D., Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors Journal of Neurosurgery 1985 63 1 2 16 (Pubitemid 15067265)
51. Trowbridge I. S., Newman R. A., Domingo D. L., Sauvage C., Transferrin receptors: structure and function Biochemical Pharmacology 1984 33 6 925 932 (Pubitemid 14171670)
52. Gatter K. C., Brown G., Trowbridge I. S., Woolston R. E., Mason D. Y., Transferrin receptors in human tissues: their distribution and possible clinical relevance Journal of Clinical Pathology 1983 36 5 539 545 (Pubitemid 13089724)
53. Trowbridge I. S., Domingo D. L., Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells Nature 1981 294 5837 171 173 (Pubitemid 12217978)
54. Recht L. D., Griffin T. W., Raso V., Salimi A. R., Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro Cancer Research 1990 50 20 6696 6700 (Pubitemid 20348802)
55. Zovickian J., Johnson V. G., Youle R. J., Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin Journal of Neurosurgery 1987 66 6 850 861 (Pubitemid 17085706)
56. Greenfield L., Johnson V. G., Youle R. J., Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity Science 1987 238 4826 536 539 (Pubitemid 17147040)
57. Laske D. W., Ilercil O., Akbasak A., Youle R. J., Oldfield E. H., Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice Journal of Neurosurgery 1994 80 3 520 526 (Pubitemid 24073015)
58. Martell L. A., Agrawal A., Ross D. A., Muraszko K. M., Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors Cancer Research 1993 53 6 1348 1353 (Pubitemid 23097115)
59. Johnson V. G., Wrobel C., Wilson D., Zovickian J., Greenfield L., Oldfield E. H., Youle R., Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia Journal of Neurosurgery 1989 70 2 240 248 (Pubitemid 19051721)
60. Giannone L., Greco F. A., Hainsworth J. D., Combination intraventricular chemotherapy for meningeal neoplasia Journal of Clinical Oncology 1986 4 1 68 73 (Pubitemid 16155963)
61. Yoon D. J., Chu D. S., Ng C. W., Pham E. A., Mason A. B., Hudson D. M., Smith V. C., MacGillivray R. T. A., Kamei D. T., Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins Journal of Controlled Release 2009 133 3 178 184
62. Nelms K., Keegan A. D., Zamorano J., Ryan J. J., Paul W. E., The IL-4 receptor: signaling mechanisms and biologic functions Annual Review of Immunology 1999 17 701 738 (Pubitemid 29241138)
63. Kondo M., Takeshita T., Ishii N., Nakamura M., Watanabe S., Arai K., Sugamura K., Sharing of the interleukin-2 (IL-2) receptor chain between receptors for IL-2 and IL-4 Science 1993 262 5141 1874 1877 (Pubitemid 24041858)
64. Russell S. M., Keegan A. D., Harada N., Nakamura Y., Noguchi M., Leland P., Friedmann M. C., Miyajima A., Puri R. K., Paul W. E., Leonard W. J., Interleukin-2 receptor chain: a functional component of the interleukin-4 receptor Science 1993 262 5141 1880 1883
65. Obiri N. I., Debinski W., Leonard W. J., Puri R. K., Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common chain shared by receptors for interleukins 2, 4, 7, 9, and 15 Journal of Biological Chemistry 1995 270 15 8797 8804
66. Obiri N. I., Leland P., Murata T., Debinski W., Puri R. K., The IL-13 receptor structure differs on various cell types and may share more than one component with il-4 receptor Journal of Immunology 1997 158 2 756 764 (Pubitemid 127492652)
67. Obiri N. I., Hillman G. G., Haas G. P., Sud S., Puri R. K., Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin- 4 Journal of Clinical Investigation 1993 91 1 88 93 (Pubitemid 23037257)
68. Obiri N. I., Siegel J. P., Varricchio F., Puri R. K., Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells Clinical and Experimental Immunology 1994 95 1 148 155 (Pubitemid 24207118)
69. Debinski W., Puri R. K., Kreitman R. J., Pastan I., A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin Journal of Biological Chemistry 1993 268 19 14065 14070 (Pubitemid 23195524)
70. Puri R. K., Debinski W., Obiri N., Kreitman R., Pastan I., Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin Cellular Immunology 1994 154 2 369 379 (Pubitemid 24115139)
71. Puri R. K., Leland P., Kreitman R. J., Pastan I., Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein International Journal of Cancer 1994 58 4 574 581 (Pubitemid 24268102)
72. Kreitman R. J., Puri R. K., Pastan I., A circularly permuted recombinant interleukin 4 toxin with increased activity Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 6889 6893
73. Kreitman R. J., Puri R. K., Pastan I., Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma Cancer Research 1995 55 15 3357 3363
74. Joshi B. H., Leland P., Asher A., Prayson R. A., Varricchio F., Puri R. K., In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures Cancer Research 2001 61 22 8058 8061 (Pubitemid 33091589)
75. Puri R. K., Hoon D. S., Leland P., Snoy P., Rand R. W., Pastan I., Kreitman R. J., Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma Cancer Research 1996 56 24 5631 5637 (Pubitemid 26422165)
76. Husain S. R., Behari N., Kreitman R. J., Pastan I., Puri R. K., Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy Cancer Research 1998 58 16 3649 3653 (Pubitemid 28376564)
77. Shimamura T., Husain S. R., Puri R. K., The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy Neurosurgical Focus 2006 20 4 E11
78. Mintz A., Gibo D. M., Slagle-Webb B., Christensen N. D., Debinski W., IL-13R 2 is a glioma-restricted receptor for interleukin-13 Neoplasia 2002 4 5 388 399
79. Kawakami M., Kawakami K., Takahashi S., Abe M., Puri R. K., Analysis of interleukin-13 receptor 2 expression in human pediatric brain tumors Cancer 2004 101 5 1036 1042 (Pubitemid 39100438)
80. Debinski W., Obiri N. I., Powers S. K., Pastan I., Puri R. K., Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin Clinical Cancer Research 1995 1 11 1253 1258
81. Husain S. R., Obiri N. I., Gill P., Zheng T., Pastan I., Debinski W., Puri R. K., Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein Clinical Cancer Research 1997 3 2 151 156 (Pubitemid 27107288)
82. Joshi B. H., Leland P., Puri R. K., Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein Croatian Medical Journal 2003 44 4 455 462 (Pubitemid 37092805)
83. Kawakami K., Kawakami M., Joshi B. H., Puri R. K., Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer Cancer Research 2001 61 16 6194 6200 (Pubitemid 32762557)
84. Debinski W., Gibo D. M., Hulet S. W., Connor J. R., Gillespie G. Y., Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas Clinical Cancer Research 1999 5 5 985 990 (Pubitemid 29233211)
85. Li C., Hall W. A., Jin N., Todhunter D. A., Panoskaltsis-Mortari A., Vallera D. A., Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice Protein Engineering 2002 15 5 419 427 (Pubitemid 34601734)
86. Rustamzadeh E., Hall W. A., Todhunter D. A., Low W. C., Liu H., Panoskaltsis-Mortari A., Vallera D. A., Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice International Journal of Cancer 2006 118 10 2594 2601
87. Kioi M., Seetharam S., Puri R. K., Targeting IL-13RA2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin Molecular Cancer Therapeutics 2008 7 6 1579 1587
88. Jarboe J. S., Johnson K. R., Choi Y., Lonser R. R., Park J. K., Expression of interleukin-13 receptor 2 in glioblastoma multiforme: implications for targeted therapies Cancer Research 2007 67 17 7983 7986 (Pubitemid 47395129)
89. Massague J., Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells Journal of Biological Chemistry 1983 258 22 13614 13620 (Pubitemid 14211998)
90. Pike L. J., Marquardt H., Todaro G. J., Transforming growth factor and epidermal growth factor stimulate the phosphorylation of a synthetic, tyrosine-containing peptide in a similar manner Journal of Biological Chemistry 1982 257 24 14628 14631 (Pubitemid 13159556)
91. Derynck R., Roberts A. B., Winkler M. E., Chen E. Y., Goeddel D. V., Human transforming growth factor- : precursor structure and expression in E. coli Cell 1984 38 1 287 297 (Pubitemid 15216556)
92. Carpenter G., Cohen S., Epidermal Growth Factor Annual Review of Biochemistry 1979 48 193 216 (Pubitemid 10191090)
93. Ushiro H., Cohen S., Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes Journal of Biological Chemistry 1980 255 18 8363 8365
94. Klijn J. G. M., Berns P. M. J. J., Schmitz P. I. M., Foekens J. A., The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients Endocrine Reviews 1992 13 1 3 17
95. Pavelic K., Banjac Z., Pavelic J., Spaventi S., Evidence for a role of EGF receptor in the progression of human lung carcinoma Anticancer Research 1993 13 4 1133 1137 (Pubitemid 23247476)
96. Rubin Grandis J., Melhem M. F., Barnes E. L., Tweardy D. J., Quantitative immunohistochemical analysis of transforming growth factor- and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck Cancer 1996 78 6 1284 1292 (Pubitemid 26303896)
97. Fox S. B., Persad R. A., Coleman N., Day C. A., Silcocks P. B., Collins C. C., Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma The British Journal of Urology 1994 74 2 214 220
98. Chow N. H., Chan S. H., Tzai T. S., Ho C. L., Liu H. S., Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder Clinical Cancer Research 2001 7 7 1957 1962
99. Yasui W., Sumiyoshi H., Hata J., Kameda T., Ochiai A., Ito H., Tahara E., Expression of epidermal growth factor receptor in human gastric and colonic carcinomas Cancer Research 1988 48 1 137 141 (Pubitemid 18030342)
100. Bartlett J. M., Langdon S. P., Simpson B. J. B., Stewart M., Katsaros D., Sismondi P., Love S., Scott W. N., Williams A. R. W., Lessells A. M., Macleod K. G., Smyth J. F., Miller W. R., The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer The British Journal of Cancer 1996 73 3 301 306 (Pubitemid 26047507)
101. Arita N., Hayakawa T., Izumoto S., Taki T., Ohnishi T., Yamamoto H., Bitoh S., Mogami H., Epidermal growth factor receptor in human glioma Journal of Neurosurgery 1989 70 6 916 919 (Pubitemid 19150511)
102. Libermann T. A., Razon N., Bartal A. D., Expression of epidermal growth factor receptors in human brain tumors Cancer Research 1984 44 2 753 760 (Pubitemid 14184614)
103. Libermann T. A., Nusbaum H. R., Razon N., Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin Nature 1985 313 5998 144 147 (Pubitemid 15192341)
104. Fuller G. N., Bigner S. H., Amplified cellular oncogenes in neoplasms of the human central nervous system Mutation Research 1992 276 3 299 306
105. Chaffanet M., Chauvin C., Laine M., Berger F., Chedin M., Rost N., Nissou M. F., Benabid A. L., EGF receptor amplification and expression in human brain tumours European Journal of Cancer 1992 28 1 11 17
106. Huang S. M., Harari P. M., Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results Investigational New Drugs 1999 17 3 259 269 (Pubitemid 30037958)
107. Kunwar S., Pai L. H., Pastan I., Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells Journal of Neurosurgery 1993 79 4 569 576 (Pubitemid 23289815)
108. Phillips P. C., Levow C., Catterall M., Colvin O. M., Pastan I., Brem H., Transforming growth factor- -Pseudomonas exotoxin fusion protein (TGF- -PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice Cancer Research 1994 54 4 1008 1015
109. Engebraaten O., Hjortland G. O., Juell S., Hirschberg H., Fodstad., Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals International Journal of Cancer 2002 97 6 846 852 (Pubitemid 34106343)
110. Liu T. F., Cohen K. A., Ramage J. G., Willingham M. C., Thorburn A. M., Frankel A. E., A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells Cancer Research 2003 63 8 1834 1837 (Pubitemid 36460845)
111. Wikstrand C. J., Reist C. J., Archer G. E., Zalutsky M. R., Bigner D. D., The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target Journal of NeuroVirology 1998 4 2 148 158 (Pubitemid 28167490)
112. Sugawa N., Ekstrand A. J., James C. D., Collins V. P., Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas Proceedings of the National Academy of Sciences of the United States of America 1990 87 21 8602 8606
113. Batra S. K., Castelino-Prabhu S., Wikstrand C. J., Zhu X., Humphrey P. A., Friedman H. S., Bigner D. D., Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene Cell Growth and Differentiation 1995 6 10 1251 1259
114. Humphrey P. A., Wong A. J., Vogelstein B., Zalutsky M. R., Fuller G. N., Archer G. E., Friedman H. S., Kwatra M. M., Bigner S. H., Bigner D. D., Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma Proceedings of the National Academy of Sciences of the United States of America 1990 87 11 4207 4211
115. Sok J. C., Coppelli F. M., Thomas S. M., Lango M. N., Xi S., Hunt J. L., Freilino M. L., Graner M. W., Wikstrand C. J., Bigner D. D., Gooding W. E., Furnari F. B., Grandis J. R., Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting Clinical Cancer Research 2006 12 17 5064 5073 (Pubitemid 44453332)
116. Wikstrand C. J., Hale L. P., Batra S. K., Hill M. L., Humphrey P. A., Kurpad S. N., McLendon R. E., Moscatello D., Pegram C. N., Reist C. J., Traweek S. T., Wong A. J., Zalutsky M. R., Bigner D. D., Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas Cancer Research 1995 55 14 3140 3148
117. Nagane M., Levitzki A., Gazit A., Cavenee W. K., Huang H. J. S., Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases Proceedings of the National Academy of Sciences of the United States of America 1998 95 10 5724 5729
118. Lorimer I. A. J., Wikstrand C. J., Batra S. K., Bigner D. D., Pastan I., Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors Clinical Cancer Research 1995 1 8 859 864
119. Lorimer I. A. J., Keppler-Hafkemeyer A., Beers R. A., Pegram C. N., Bigner D. D., Pastan I., Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display Proceedings of the National Academy of Sciences of the United States of America 1996 93 25 14815 14820 (Pubitemid 26419052)
120. Archer G. E., Sampson J. H., Lorimer I. A. J., McLendon R. E., Kuan C. T., Friedman A. H., Friedman H. S., Pastan I. H., Bigner D. D., Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1 Clinical Cancer Research 1999 5 9 2646 2652 (Pubitemid 29437353)
121. Beers R., Chowdhury P., Bigner D., Pastan I., Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display Clinical Cancer Research 2000 6 7 2835 2843 (Pubitemid 30482125)
122. Sampson J. H., Brady M., Raghavan R., Mehta A. I., Friedman A. H., Reardon D. A., Petry N. A., Barboriak D. P., Wong T. Z., Zalutsky M. R., Lally-Goss D., Bigner D. D., Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans Neurosurgery 2011 69 3 668 676
123. Loging W. T., Lal A., Siu I. M., Loney T. L., Wikstrand C. J., Marra M. A., Prange C., Bigner D. D., Strausberg R. L., Riggins G. J., Identifying potential tumor markers and antigens by database mining and rapid expression screening Genome Research 2000 10 9 1393 1402
124. Kuan C. T., Wakiya K., Dowell J. M., Herndon J. E., Reardon D. A., Graner M. W., Riggins G. J., Wikstrand C. J., Bigner D. D., Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme Clinical Cancer Research 2006 12 7 1970 1982
125. Kuan C.T., Wakiya K., Keir S.T., Affinity-matured anti-glycoprotein nmb recombinant immunotoxins targeting malignant gliomas and melanomas International Journal of Cancer 2011 129 111 121
126. Pluschke G., Vanek M., Evans A., Dittmar T., Schmid P., Itin P., Filardo E. J., Reisfeld R. A., Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan Proceedings of the National Academy of Sciences of the United States of America 1996 93 18 9710 9715 (Pubitemid 26296674)
127. Schrappe M., Klier F. G., Spiro R. C., Waltz T. A., Reisfeld R. A., Gladson C. L., Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells Cancer Research 1991 51 18 4986 4993
128. Hjortland G. O., Garman-Vik S. S., Juell S., Olsen. E., Hirschberg H., Fodstad., Engebraaten O., Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme Journal of Neurosurgery 2004 100 2 320 327 (Pubitemid 38140237)
129. Carrel S., Accolla R. S., Carmagnola A. L., Mach J. P., Common human melanoma-associated antigen(s) detected by monoclonal antibodies Cancer Research 1980 40 7 2523 2528 (Pubitemid 10082277)
130. Kurpad S. N., Zhao X. G., Wikstrand C. J., Batra S. K., McLendon R. E., Bigner D. D., Tumor antigens in astrocytic gliomas Glia 1995 15 3 244 256
131. Bigner D. D., Brown M., Coleman R. E., Friedman A. H., Friedman H. S., McLendon R. E., Bigner S. H., Zhao X. G., Wikstrand C. J., Pegram C. N., Kerby T., Zalutsky M. R., Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F(ab')2a preliminary report Journal of Neuro-Oncology 1995 24 1 109 122
132. Cokgor I., Akabani G., Friedman H. S., Friedman A. H., Zalutsky M. R., Zehngebot L. M., Provenzale J. M., Guy C. D., Wikstrand C. J., Bigner D. D., Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)2: a case study Cancer 2001 91 9 1809 1813 (Pubitemid 32377968)
133. Ayriss J., Reisfeld R., Kuan C. T., Keir S., Pastan I., Bigner D. D., Mel-14 and 9.2.27 immunotoxins: promising therapeutics for pediatric glioma Proceedings of the Pediatric Neuro-Oncology Basic and Translational Research Conference May 2011 New Orleans, LA, USA
134. Eph Nomenclature Committee, Unified nomenclature for eph family receptors and their ligands, the ephrins Cell 1997 90 403 404
135. Kullander K., Klein R., Mechanisms and functions of Eph and ephrin signalling Nature Reviews Molecular Cell Biology 2002 3 7 475 486 (Pubitemid 34733429)
136. Wykosky J., Gibo D. M., Debinski W., A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells Molecular Cancer Therapeutics 2007 6 12 3208 3218
137. Wykosky J., Gibo D. M., Stanton C., Debinski W., EphA2 as a novel molecular marker and target in glioblastoma multiforme Molecular Cancer Research 2005 3 10 541 551 (Pubitemid 41567273)
138. Smith H. W., Marshall C. J., Regulation of cell signalling by uPAR Nature Reviews Molecular Cell Biology 2010 11 1 23 36
139. Vallera D. A., Li C., Jin N., Panoskaltsis-Mortari A., Hall W. A., Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT Journal of the National Cancer Institute 2002 94 8 597 606 (Pubitemid 34498647)
140. Stish B. J., Oh S., Vallera D. A., Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model Journal of Neuro-Oncology 2008 87 1 51 61
141. Oh S., Tsai A. K., Ohlfest J. R., Panoskaltsis-Mortari A., Vallera D. A., Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain: laboratory investigation Journal of Neurosurgery 2011 114 6 1662 1671
142. Todhunter D. A., Hall W. A., Rustamzadeh E., Shu Y., Doumbia S. O., Vallera D. A., A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model Protein Engineering, Design and Selection 2004 17 2 157 164 (Pubitemid 38477742)
143. Vandergrift W. A., Patel S. J., Nicholas J. S., Varma A. K., Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas Neurosurgical Focus 2006 20 4 E13
144. Onda M., Beers R., Xiang L., Nagata S., Wang Q. C., Pastan I., An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes Proceedings of the National Academy of Sciences of the United States of America 2008 105 32 11311 11316
145. Zalutsky M. R., Current status of therapy of solid tumors: brain tumor therapy Journal of Nuclear Medicine 2005 46 1 151S 156S (Pubitemid 47619030)
146. Zalutsky M. R., Boskovitz A., Kuan C. T., Pegram C. N., Ayriss J., Wikstrand C. J., Buckley A. F., Lipp E. S., Herndon J. E. II, McLendon R. E., Bigner D. D., Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors Nuclear Medicine and Biology 2012 39 1 23 34
147. Kato Y., Vaidyanathan G., Kaneko M. K., Mishima K., Srivastava N., Chandramohan V., Pegram C., Keir S. T., Kuan C. T., Bigner D. D., Zalutsky M. R., Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas Nuclear Medicine and Biology 2010 37 7 785 794